What's Happening?
The Centers for Medicare and Medicaid Services (CMS) has finalized its Outpatient Prospective Payment System and Medicare Physician Fee Schedule rules for 2027, introducing several key changes affecting nuclear medicine and imaging professionals. CMS will
continue using arithmetic Mean Unit Cost (MUC) for non-passthrough diagnostic radiopharmaceuticals due to data quality concerns, rather than transitioning to Average Sales Price (ASP)-based payment. The agency also finalized a proposal to expand its site-neutral payment policy, implementing a 60% cut to Outpatient Prospective Payment System (OPPS) rates for imaging without contrast services provided in most off-campus hospital outpatient departments. These services include bone density scans, x-rays, ultrasounds, CT scans, and MRIs, with rural sole community hospitals being exempt. Additionally, CMS finalized an ASP minus 28% rate for 340B-acquired drugs, a reduction from the proposed ASP minus 33.4%, effective January 1, 2027.
Why It's Important?
These finalized policies will have a significant financial impact on healthcare providers, particularly those in nuclear medicine and imaging. The site-neutral payment expansion is estimated to reduce Medicare Part B expenditures by approximately $260 million in the first year, including $190 million in Part B savings and $70 million in reduced beneficiary premiums. While beneficiaries may see reduced cost-sharing, hospitals' overall imaging budgets could be negatively affected, potentially impacting services and access. The decision to maintain MUC for radiopharmaceuticals and the ASP minus 28% rate for 340B drugs reflect CMS's ongoing efforts to control costs within the Medicare program. However, the expiration of a temporary 2.5% payment increase, coupled with minimal baseline updates, means physicians and healthcare professionals will face a net Medicare cut in 2027, prompting calls for congressional intervention to establish predictable annual updates tied to practice cost inflation.
What's Next?
Attention is now turning to Congress to address the impending Medicare cuts for physicians and healthcare professionals in 2027. Stakeholders are advocating for legislative action to not only prevent these cuts but also to establish a more predictable annual update mechanism tied to practice cost inflation. For nuclear medicine, the reorganization of APCs and CPT code assignments will require careful review by practitioners to understand the specific impacts on their practices. CMS has indicated it will continue developing guidance for an ASP Reporting Framework for diagnostic radiopharmaceuticals and welcomes stakeholder input, suggesting potential future changes in this area. The agency also left the door open for future rulemaking regarding the expansion of exemptions for 340B drug payment rates and the formal criteria for identifying Software as a Medical Service (SaMS) codes, indicating ongoing evolution in Medicare payment policies.
Beyond the Headlines
The CMS's finalized payment policies underscore a broader trend of cost containment within the U.S. healthcare system, particularly within Medicare. The expansion of site-neutral payments reflects an effort to equalize reimbursement rates across different care settings, aiming to reduce incentives for hospitals to acquire physician practices and charge higher facility fees for services that could be provided in lower-cost settings. While intended to save money, this policy could lead to financial strain for some hospital outpatient departments, potentially affecting their ability to invest in new technology or maintain services. The ongoing debate over drug pricing, exemplified by the 340B program adjustments and the radiopharmaceutical payment methods, highlights the complex challenge of balancing pharmaceutical innovation, provider sustainability, and patient affordability. These decisions will likely fuel continued advocacy from various healthcare sectors seeking to influence future Medicare policy directions.













